Here are the DEF 14A proxy statements from Protalix BioTherapeutics, Inc. (PLX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLX filings page.
Protalix BioTherapeutics, Inc. will hold its 2026 annual stockholder meeting on June 25, 2026 in Tel Aviv. Holders of the 80,571,642 shares of common stock outstanding as of April 30, 2026 may vote.
Stockholders are asked to elect eight directors for one-year terms, approve on a non-binding advisory basis the compensation of named executive officers, and approve an amended and restated 2006 Stock Incentive Plan that raises the share reserve from 17,475,171 to 20,975,171 shares. They will also vote on ratifying Kesselman & Kesselman as independent auditor for 2026 and any other proper business.
The proxy details board and committee composition, independence, ownership and extensive executive pay information. In 2025, CEO Dror Bashan received total compensation of $1.17 million, while all directors and executive officers collectively beneficially owned about 5,576,142 shares, or 6.7% of the common stock.